Cargando…

Effects of lifestyle modification on liver enzyme and Fibroscan in Indian patients with non-alcoholic fatty liver disease

BACKGROUND AND AIMS: Non-alcoholic fatty liver disease (NAFLD) is remarkably increasing in developing countries like India, in parallel with the increasing incidence of obesity. Lifestyle modification is a recommended treatment for NAFLD. In most of the previous studies, improvement after lifestyle...

Descripción completa

Detalles Bibliográficos
Autores principales:	Paul, Jayanta, Venugopal, Raj Vigna, Peter, Lorance, Hussain, Shihaz, Naresh Kumar Shetty, Kula, Shetti, Mohit P
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5806404/ https://www.ncbi.nlm.nih.gov/pubmed/29479443 http://dx.doi.org/10.1093/gastro/gox020

Ejemplares similares

Fibroscan for assessing liver fibrosis: An acceptable alternative for liver biopsy: Fibroscan: an acceptable alternative for liver biopsy
por: Malekzadeh, Reza, et al.
Publicado: (2011)

Estimation of Liver Fat by FibroScan in Patients With Nonalcoholic Fatty Liver Disease
por: Shrestha, Rupesh, et al.
Publicado: (2021)

Diagnostic Performance of Ultrasonography in Detecting Fatty Liver Disease in Comparison with Fibroscan in People Suspected of Fatty Liver
por: Kamali, Leila, et al.
Publicado: (2019)

FibroScan Detection of Fatty Liver/Liver Fibrosis in 2266 Cases of Chronic Hepatitis B
por: He, Tingshan, et al.
Publicado: (2020)

Update of liver fibrosis and steatosis with transient elastography (Fibroscan)
por: Wong, Grace Lai-Hung
Publicado: (2013)

The role of FibroScan in the era of metabolic (dysfunction)-associated fatty liver disease
por: Yilmaz, Yusuf, et al.
Publicado: (2023)

Correlation between Fibroscan and laboratory tests in non-alcoholic fatty liver disease/non-alcoholic steatohepatitis patients for assessing liver fibrosis
por: Al Danaf, Layal, et al.
Publicado: (2022)

The discriminatory ability of FibroScan liver stiffness measurement, controlled attenuation parameter, and FibroScan–aspartate aminotransferase to predict severity of liver disease in children
por: Chaidez, Alexander, et al.
Publicado: (2022)

Quantitative Evaluation of Liver Fibrosis on T1 Relaxometry in Comparison with Fibroscan
Publicado: (2020)

Liver stiffness (Fibroscan®) is a predictor of all‐cause mortality in people with non‐alcoholic fatty liver disease
por: Braude, Michael, et al.
Publicado: (2022)

Diagnostic Accuracy of FIB-4 and FIB-5 Scores as Compared to Fibroscan for Assessment of Liver Fibrosis in Patients With Non-Alcoholic Fatty Liver Disease
por: Kumari, Bandana, et al.
Publicado: (2021)

Combination of Fibrosis-4, liver-stiffness measurement, and Fibroscan-AST score to predict liver-related outcomes in nonalcoholic fatty liver disease
por: Wong, Yu Jun, et al.
Publicado: (2023)

Accuracy of FibroScan in analysis of liver fibrosis in patients with concomitant chronic Hepatitis B and nonalcoholic fatty liver disease
por: Li, Qiang, et al.
Publicado: (2020)

Performance of liver stiffness measurements obtained with FibroScan is affected by glucose metabolism in patients with nonalcoholic fatty liver disease
por: Yang, Xinyu, et al.
Publicado: (2021)

Validation of Novel Fibrosis Index (NFI) for assessment of liver fibrosis: comparison with transient elastography (FibroScan)
por: Hussain, Azhar, et al.
Publicado: (2019)

Changes in the etiology of chronic liver disease by referral to a FibroScan center: Increasing prevalence of the nonalcoholic fatty liver disease
por: Eris, Tansu, et al.
Publicado: (2023)

Liver Hemangioma Might Lead to overestimation of Liver Fibrosis by Fibroscan; A Missed Issue in Two Cases
por: Aalaei-Andabili, Seyed Hossein, et al.
Publicado: (2012)

The association of weight gain with nonalcoholic fatty liver disease and fibrosis detected by FibroScan in the United States
por: Wijarnpreecha, Karn, et al.
Publicado: (2022)

Association between body roundness index and non‐alcoholic fatty liver disease detected by Fibroscan in America
por: Jiang, Ningning, et al.
Publicado: (2023)

The clinical utility of FibroScan(®) as a noninvasive diagnostic test for liver disease
por: Wilder, Julius, et al.
Publicado: (2014)

Fibroscan improves the diagnosis sensitivity of liver fibrosis in patients with chronic hepatitis B
por: HUANG, RENGANG, et al.
Publicado: (2016)

A prospective comparative assessment of the accuracy of the FibroScan in evaluating liver steatosis
por: Jun, Baek Gyu, et al.
Publicado: (2017)

Liver Stiffness Measurement With FibroScan: Use the Right Probe in the Right Conditions!
por: Berger, Arthur, et al.
Publicado: (2019)

Fibroscan Compared to FIB-4, APRI, and AST/ALT Ratio for Assessment of Liver Fibrosis in Saudi Patients With Nonalcoholic Fatty Liver Disease
por: Fallatah, Hind I., et al.
Publicado: (2016)

Laboratory Tests, Liver Vessels Color Doppler Sonography, and FibroScan Findings in Patients with Nonalcoholic Fatty Liver Disease: An Observation Study
por: Alizadeh, Ahmad, et al.
Publicado: (2018)

Prediction of Liver-Related Events Using Fibroscan in Chronic Hepatitis B Patients Showing Advanced Liver Fibrosis
por: Kim, Seung Up, et al.
Publicado: (2012)

Attenuation parameter and liver stiffness measurement using FibroTouch vs Fibroscan in patients with chronic liver disease
por: Ng, Ying Zhuang, et al.
Publicado: (2021)

Cost-comparison analysis of FIB-4, ELF and fibroscan in community pathways for non-alcoholic fatty liver disease
por: Srivastava, Ankur, et al.
Publicado: (2019)

Utility of Fibroscan XL to assess the severity of non-alcoholic fatty liver disease in patients undergoing bariatric surgery
por: Yang, Andrew, et al.
Publicado: (2021)

Utility of FibroScan-based scoring systems to narrow the risk group of nonalcoholic fatty liver disease with comorbidities
por: Miura, Kouichi, et al.
Publicado: (2022)

Comparison of ELF, FibroTest and FibroScan for the non-invasive assessment of liver fibrosis
por: Friedrich-Rust, Mireen, et al.
Publicado: (2010)

Can We Accurately Assess Liver Fibrosis with Fibroscan® Using Fewer Valid Measurements?
por: Pournik, Omid, et al.
Publicado: (2013)

Safety Profile of Liver FibroScan in Patients with Cardiac Pacemakers or Implantable Cardioverter-Defibrillators
por: Chan, Yin, et al.
Publicado: (2017)

Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes: Evaluation of Hepatic Fibrosis and Steatosis Using Fibroscan
por: Tuong, Tran Thi Khanh, et al.
Publicado: (2020)

The FibroScan-aspartate aminotransferase score can stratify the disease severity in a Japanese cohort with fatty liver diseases
por: Fujii, Hideki, et al.
Publicado: (2021)

Comparative Accuracy of Clinical Fibrosis Markers, Hepascore and Fibroscan® to Detect Advanced Fibrosis in Patients with Nonalcoholic Fatty Liver Disease
por: Bertot, Luis C., et al.
Publicado: (2023)

Use of aspartate aminotransferase to platelet ratio to reduce the need for FibroScan in the evaluation of liver fibrosis
por: Wong, Stephanie, et al.
Publicado: (2017)

Spectrum of liver diseases in patients referred for Fibroscan: A single center experience in the Middle East
por: Sawaf, Bisher, et al.
Publicado: (2020)

Discordance between Liver Biopsy and FibroScan® in Assessing Liver Fibrosis in Chronic Hepatitis B: Risk Factors and Influence of Necroinflammation
por: Kim, Seung Up, et al.
Publicado: (2012)

Non-alcoholic fatty liver disease and lifestyle modifications, focusing on physical activity
por: Kwak, Min-Sun, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_v0qdmsmc51ppaifn4jbmcfecgd